Structured Review

Illumina Inc truseq amplicon panel
Truseq Amplicon Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 89/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/truseq amplicon panel/product/Illumina Inc
Average 89 stars, based on 10 article reviews
Price from $9.99 to $1999.99
truseq amplicon panel - by Bioz Stars, 2020-07
89/100 stars

Related Products / Commonly Used Together

input dna
dna library
iontorrent ampliseq panel
ampliseq panel

Images

Related Articles

Sequencing:

Article Title: A Pathway-Centric Survey of Somatic Mutations in Chinese Patients with Colorectal Carcinomas
Article Snippet: .. DNA library was prepared using Illumina TruSeq Amplicon panel; 5 ul of each library was pooled and Kapa q-PCR was used for concentration checking before MiSeq sequencing. .. Statistical analysis and somatic mutation detection We used the Illumina Experiment Manager to define the sample sheet, and the sample library was loaded into the MiSeq reagent cartridge for automated cluster generation and sequencing.

Concentration Assay:

Article Title: A Pathway-Centric Survey of Somatic Mutations in Chinese Patients with Colorectal Carcinomas
Article Snippet: .. DNA library was prepared using Illumina TruSeq Amplicon panel; 5 ul of each library was pooled and Kapa q-PCR was used for concentration checking before MiSeq sequencing. .. Statistical analysis and somatic mutation detection We used the Illumina Experiment Manager to define the sample sheet, and the sample library was loaded into the MiSeq reagent cartridge for automated cluster generation and sequencing.

Amplification:

Article Title: Amplicon Sequencing of Colorectal Cancer: Variant Calling in Frozen and Formalin-Fixed Samples
Article Snippet: .. Remarkably, large differences exist between the recommended amounts of input DNA between Illumina TruSeq amplicon panel ( > 250ng) and IonTorrent AmpliSeq panel, for which libraries can be prepared with as little as 10ng DNA. .. Larger series of FFPE samples have to be sequenced to show feasibility for routine practice and clinical studies.

Article Title: A Pathway-Centric Survey of Somatic Mutations in Chinese Patients with Colorectal Carcinomas
Article Snippet: .. DNA library was prepared using Illumina TruSeq Amplicon panel; 5 ul of each library was pooled and Kapa q-PCR was used for concentration checking before MiSeq sequencing. .. Statistical analysis and somatic mutation detection We used the Illumina Experiment Manager to define the sample sheet, and the sample library was loaded into the MiSeq reagent cartridge for automated cluster generation and sequencing.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Illumina Inc truseq amplicon cancer panels
    Intragenic copy number detection and comparison to commercial panels. ( A ) Control genomic DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon duplications in BRCA1 , TP53 and MSH2 , which were assessed by the DeCON tool. Exons are numbered along the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. ( B ) A commercially available pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina <t>TruSeq</t> <t>Amplicon</t> – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually targeted by the panels.
    Truseq Amplicon Cancer Panels, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/truseq amplicon cancer panels/product/Illumina Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    truseq amplicon cancer panels - by Bioz Stars, 2020-07
    93/100 stars
      Buy from Supplier

    93
    Illumina Inc truseq amplicon cancer panel tscap
    Intragenic copy number detection and comparison to commercial panels. ( A ) Control genomic DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon duplications in BRCA1 , TP53 and MSH2 , which were assessed by the DeCON tool. Exons are numbered along the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. ( B ) A commercially available pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina <t>TruSeq</t> <t>Amplicon</t> – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually targeted by the panels.
    Truseq Amplicon Cancer Panel Tscap, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/truseq amplicon cancer panel tscap/product/Illumina Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    truseq amplicon cancer panel tscap - by Bioz Stars, 2020-07
    93/100 stars
      Buy from Supplier

    91
    Illumina Inc truseq amplicon cancer panel
    Oncoprint visualizing the gene mutation status of APC , KRAS , NRAS , BRAF , PIK3CA , TP53 , FBXW7 and SMAD4 assessed by <t>TruSeq</t> <t>Amplicon</t> Cancer Panel TSACP analysis for stage II ( n = 29) and stage III ( n = 31) colon cancers The rows indicate the gene mutation status of the 60 samples (grey bars) and the black spots depict mutations.
    Truseq Amplicon Cancer Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 91/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/truseq amplicon cancer panel/product/Illumina Inc
    Average 91 stars, based on 43 article reviews
    Price from $9.99 to $1999.99
    truseq amplicon cancer panel - by Bioz Stars, 2020-07
    91/100 stars
      Buy from Supplier

    Image Search Results


    Intragenic copy number detection and comparison to commercial panels. ( A ) Control genomic DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon duplications in BRCA1 , TP53 and MSH2 , which were assessed by the DeCON tool. Exons are numbered along the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. ( B ) A commercially available pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina TruSeq Amplicon – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually targeted by the panels.

    Journal: Scientific Reports

    Article Title: Development and validation of a targeted gene sequencing panel for application to disparate cancers

    doi: 10.1038/s41598-019-52000-3

    Figure Lengend Snippet: Intragenic copy number detection and comparison to commercial panels. ( A ) Control genomic DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon duplications in BRCA1 , TP53 and MSH2 , which were assessed by the DeCON tool. Exons are numbered along the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. ( B ) A commercially available pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina TruSeq Amplicon – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually targeted by the panels.

    Article Snippet: Firstly, genes were selected from the following commercially available panels: TruSight Tumour 26 and TruSeq Amplicon Cancer Panels (Illumina), SureSeq Solid Tumour panel (Oxford Gene Technology), Foundation One Panel (Foundation Medicine), OncoCarta Panels Versions 1–3 (OncoCarta) and Haloplex Cancer Research Panel (Agilent).

    Techniques: Variant Assay, Amplification

    Intragenic copy number detection and comparison to commercial panels. ( A ) Control genomic DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon duplications in BRCA1 , TP53 and MSH2 , which were assessed by the DeCON tool. Exons are numbered along the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. ( B ) A commercially available pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina TruSeq Amplicon – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually targeted by the panels.

    Journal: Scientific Reports

    Article Title: Development and validation of a targeted gene sequencing panel for application to disparate cancers

    doi: 10.1038/s41598-019-52000-3

    Figure Lengend Snippet: Intragenic copy number detection and comparison to commercial panels. ( A ) Control genomic DNA samples were acquired from kConFab for sensitivity testing. Three of these samples included known exon duplications in BRCA1 , TP53 and MSH2 , which were assessed by the DeCON tool. Exons are numbered along the x-axis, and those of normal copy number are presented as blue dots. Amplifications are shown in red. The TP53 and AURKB genes are on opposing DNA strands hence the presence of the latter and its exons in this Figure. A similar genetic-overlap is observed for MSH2 to the left of the panel. ( B ) A commercially available pool of synthetic oligos against a normal genomic background was also obtained. Mutations were provided at variant allele frequencies (VAF) of 5–15% and 15–35%, or at germline frequencies. Presented are the number of detected and missed variants in our PV1 and PV2 panels relative to what was expected in AcroMetrix. This was compared to three other panels [AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina TruSeq Amplicon – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP)], the data for which were provided by the AcroMetrix manufacturer. Percent values on the right indicate the proportion of AcroMetrix variants actually targeted by the panels.

    Article Snippet: In comparison to the three other commercial sequencing panels presented in Fig. , our panel had greater breadth, targeting 100% of the AcroMetrix oligo pool, and greater sensitivity, detecting proportionally more expected variants, with AmpliSeq Cancer Hotspot Panel v2 (CHPv2), Illumina’s TruSeq Amplicon – Cancer Panel (TSCAP) and TruSight Tumor Panel 26 (TSTP) detecting 98.8%, 97.1% and 97.4% of their respective targets.

    Techniques: Variant Assay, Amplification

    Oncoprint visualizing the gene mutation status of APC , KRAS , NRAS , BRAF , PIK3CA , TP53 , FBXW7 and SMAD4 assessed by TruSeq Amplicon Cancer Panel TSACP analysis for stage II ( n = 29) and stage III ( n = 31) colon cancers The rows indicate the gene mutation status of the 60 samples (grey bars) and the black spots depict mutations.

    Journal: Oncotarget

    Article Title: Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients

    doi: 10.18632/oncotarget.12510

    Figure Lengend Snippet: Oncoprint visualizing the gene mutation status of APC , KRAS , NRAS , BRAF , PIK3CA , TP53 , FBXW7 and SMAD4 assessed by TruSeq Amplicon Cancer Panel TSACP analysis for stage II ( n = 29) and stage III ( n = 31) colon cancers The rows indicate the gene mutation status of the 60 samples (grey bars) and the black spots depict mutations.

    Article Snippet: Detection of gene mutations Mutation status of APC , TP53 , KRAS , PIK3CA , FBXW7 , SMAD4 , BRAF and NRAS , i.e. genes that are commonly mutated in CRC, was assessed by next generation sequencing analysis of FFPE DNA samples using the TruSeq Amplicon Cancer Panel (TSACP; Illumina Inc, San Diego, CA USA).

    Techniques: Mutagenesis, Amplification

    Mutation frequency by gene from results of ( a ) MALDI-TOF, n = 827, and ( b ) TruSeq Amplicon Cancer Panel, n = 792. Mutation frequency was calculated as number of variant occurrences within each gene divided by the total number of patients

    Journal: Genome Medicine

    Article Title: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

    doi: 10.1186/s13073-016-0364-2

    Figure Lengend Snippet: Mutation frequency by gene from results of ( a ) MALDI-TOF, n = 827, and ( b ) TruSeq Amplicon Cancer Panel, n = 792. Mutation frequency was calculated as number of variant occurrences within each gene divided by the total number of patients

    Article Snippet: TruSeq Amplicon Cancer Panel

    Techniques: Mutagenesis, Amplification, Variant Assay

    Distribution of patients by tumor site and most actionable variant identified [ 4 ]. Cases tested with TruSeq Amplicon Cancer Panel (TSACP; n = 792) are shown in ( a ) and ( b ); cases tested by MALDI-TOF MS (n = 827) are shown in ( c ) and ( d ). a Proportion and number of variants by tumor site, TSACP. b Actionability of variants by tumor site, TSACP. c Proportion and number of variants by tumor site, MALDI-TOF. d Actionability of variants per case by tumor site, MALDI-TOF. Patients with more than one variant were counted once by their most actionable variant class. Total number of patients is indicated by value within or below each bar section . “Gyne-other” includes cervical, endometrial, fallopian tube, uterine, and vulvar

    Journal: Genome Medicine

    Article Title: Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

    doi: 10.1186/s13073-016-0364-2

    Figure Lengend Snippet: Distribution of patients by tumor site and most actionable variant identified [ 4 ]. Cases tested with TruSeq Amplicon Cancer Panel (TSACP; n = 792) are shown in ( a ) and ( b ); cases tested by MALDI-TOF MS (n = 827) are shown in ( c ) and ( d ). a Proportion and number of variants by tumor site, TSACP. b Actionability of variants by tumor site, TSACP. c Proportion and number of variants by tumor site, MALDI-TOF. d Actionability of variants per case by tumor site, MALDI-TOF. Patients with more than one variant were counted once by their most actionable variant class. Total number of patients is indicated by value within or below each bar section . “Gyne-other” includes cervical, endometrial, fallopian tube, uterine, and vulvar

    Article Snippet: TruSeq Amplicon Cancer Panel

    Techniques: Variant Assay, Amplification, Mass Spectrometry